News | March 01, 2024
Pfizer Oncology hosts innovation day
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
Demonstrate significant bleed reduction in hemophilia A and B
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Approval to dramatically change CAR-T therapies landscape
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
Subscribe To Our Newsletter & Stay Updated
